top of page
Laboratory work for GET-IN doctoral network

Project DC5

Development and validation of novel gene editing delivery vehicles ‘nanoblades’ retargeted to T cells and hematopoietic stem cells

PROJECT INFORMATION

Host institution of GET-IN the INSERM

Host institution: INSERM, France

Supervisory team: Prof. Els Verhoeyen (INSERM, Université Côte d’Azur), Prof. Rik Gijsbers (KU Leuven), Dr; Otto-Wilhelm Merten (Miltenyi Biotech)

PROJECT DESCRIPTION 

This project is situated in the field of novel modalities to deliver gene therapy. The objectives are: (1) To pseudotype nanoblades (gene editing delivery vehicles) using novel paramyxovirus glycoproteins (gps) in order to redirect them to T Cells or HSCs. (2) To evaluate the targeting efficiency of these nanoblades in vitro. (3) Up-scaling and improving the production of the novel nanoblades. (4) in vivo evaluation of novel nanoblades in patient cells and humanised mice. The project will involve wet lab work including viral vector production and testing in relevant animal models.


A successful project will result in: (1) Nanoblades efficiently targeting T cells and HSCs. (2) Optimised production protocol for retargeted nanoblades.


Enrolment in Doctoral School: Université Côte d’Azur (Nice)


Planned secondments:

  • KU Leuven, Belgium (M19-22): Upscaling and QC of novel nanoblade production; 

  • University of Tübingen, Germany (28-29): evaluation of nanoblades in OoC models; 

  • Miltenyi Biotech, Germany (EP, M38): Working in GMP environments.

GET-IN logo and organisation name

This project has received funding from the European Union’s Framework Programme for Research and Innovation, Horizon Europe under Grant Agreement No. 101119880

ON5b, Herestraat 49, Box 1023

3000 Leuven, Belgium

Follow us on 

  • Linkedin
Partner logos

©2023 by GET-IN. Made with pride by Websters

Funded by the European Union banner
bottom of page